JY231(JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia(B-ALL)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
B-cell Acute Lymphoblastic Leukemia( B-ALL )
Interventions
BIOLOGICAL

JY231

Infusion of JY231 Injection by dose of 1-10×10\^6 Transduction Units(TU)/ kg、1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg. Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)

Trial Locations (1)

Unknown

RECRUITING

920th HJointLogistics, Kunming

All Listed Sponsors
lead

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

OTHER